Low-Energy Stereotactic Radiotherapy for Treatment of Exudative Age-Related Macular Degeneration in a Treat-and-Extend Regimen
Low-Energy Stereotactic Radiotherapy for Treatment of Exudative Age-Related Macular Degeneration in a Treat-and-Extend Regimen
复制标题
DOI：
10.3928/23258160-20180129-02
复制
发表时间：
2018-02-01
影响因子：
1
通讯作者：
Prunte, Christian
中科院分区：
文献类型：
--
作者：
Hatz, Katja;Zimmermann, Frank;Prunte, Christian
背景和目的：评估治疗延长方案（TER）后低能量立体定向放射治疗（SRT）联合抗血管内皮生长因子（VEGF）治疗湿性年龄相关性黄斑变性（AMD）的有效性和安全性。 患者和方法：在 SRT 之前/之后，作者比较了 50 名需要频繁抗 VEGF 治疗（每 4 或 6 周）的湿性 AMD 患者的回顾性连续病例系列。进行一次 SRT 和 TER（SRT 前/后的方式相同）。结果为视力 (VA)、无复发间隔和中央视网膜厚度 (CRT)。 结果：SRT 后，CRT 从基线 (407.3 μm +/- 153.2 μm) 降低至 12 个月 (320.2 μm +/- 112.1 μm)；P
BACKGROUND AND OBJECTIVE: To evaluate the effectiveness and safety of low-energy stereotactic radiotherapy (SRT) combined with anti-vascular endothelial growth factor (VEGF) treatment following a treat-and-extend regimen (TER) in wet age-related macular degeneration (AMD).PATIENTS AND METHODS: Before/after SRT, the authors compared retrospective consecutive case series of 50 patients requiring frequent anti-VEGF treatment (every 4 or 6 weeks) in wet AMD, treated with a single session of SRT and TER (same manner pre/post-SRT). Outcomes were visual acuity (VA), recurrence-free interval, and central retinal thickness (CRT).RESULTS: After SRT, CRT was reduced from baseline (407.3 mu m +/- 153.2 mu m) to 12 months (320.2 mu m +/- 112.1 mu m; P